Skip to content
Precision for Medicine
Contact Us
PFM nanoString nCounter® Assays PFM nanoString nCounter® Assays

NanoString nCounter® Technology

NanoString technology provides a unique way to quickly analyze several hundred distinct gene or protein targets simultaneously using barcoded counting
For preclinical and clinical studies that need highly multiplexed, quantitative gene expression data, NanoString assays can provide rich and useful biomarker data. In addition, NanoString gene expression technology is compatible with low abundance samples like cell-free DNA from liquid biopsies, and low-quality samples such as legacy and FFPE specimens. Precision’s scientific experts can recommend a validated panel or other approach to suit your study and can perform NanoString assays as either an individual service, or as part of a comprehensive therapeutic development package, including biomarker assays and clinical trials.
0E5A8205

Advantages of nanoString gene expression assays

  • Multiplex up to 800 distinct genes
  • Directly detect RNA for accurate quantitation
  • Work with old or poor-quality samples, such as FFPE tissue
  • Work with low-abundance samples such as cfDNA from liquid biopsies
  • Can utilize predesigned panels of 770 genes (these panels can be customized with an additional 30 genes)
    • PanCancer Pathways Panel
    • PanCancer Immune Profiling Panel
    • PanCancer Progression Panel
    • PanCancer IO360™ Gene Expression Panel

Tumor analysis and immune profiling using nanoString technology

By analyzing up to 800 genes (770 standard and up to 30 customized target genes of interest), we can monitor checkpoint inhibitor status and profile the body’s immune response, determining hot/cold tumor status.

Precision specializes in using these and other custom panels to support oncology therapeutic development, as well as to monitor immune status to support development of autoimmune indication therapies.

Example uses of nanoString nCounter® in clinical development

  • iStock-1441786721

    Autoimmune: Phase 2b clinical study in atopic dermatitis

    Antibody therapy targeting effector and memory immune responses. Precision recommended the PanCancer Immune Profiling Panel in conjunction with a custom panel of 14 genes. Result: Determined 4 biomarker key endpoints correlating with patient response.
  • oncology-2-1

    Oncology: Phase 1/2 clinical trial to determine method of action

    Therapy to target patients with metastatic solid tumor. Precision recommended the PanCancer Immune Profiling Panel to analyze 770 genes from 24 different immune cell types, common checkpoint inhibitors, and genes covering both adaptive and innate immune response
  • iStock-1446239060

    Oncology: Phase 1/2 trial in solid tumors

    Precision recommended an nCounter Copy Number Variation CodeSet to determine gene copy number in 8 targeted genes in biopsy samples

Learn more about our genomics solutions

Brochure

Brochure: Genomics Platforms and Solutions

Download Brochure
Brochure: Genomics Platforms and Solutions
Woman working in a lab

Global reach, multi-site support

Our ApoStream® services support preclinical and clinical research, including multi-site studies, conducted anywhere in the world.

Working with Precision

Precision’s specialty lab scientists take a collaborative and consultative approach to projects and can provide recommendations on biomarker assay strategies and implementation. Services can be provided individually or as part of a comprehensive therapeutic development package including biomarker assays and clinical trials.

Related services

  • Explore

    ddPCR

    Advanced ddPCR applications from preclinical to clinical assays including gene therapy viral shedding and CAR-T biodistribution
    Explore
  • Explore

    NGS

    Services including RNA-seq, whole exome sequencing, and targeted DNA/RNA sequencing utilizing both Illumina and Thermo-Fisher NGS platforms
    Explore
  • Explore

    FISH/ISH

    Development of multiplex FISH/ISH assays to detect abnormalities in a range of tissues, including hematological and solid organ tumors
    Explore

Explore the Precision blog

Read our blog to gain more insights and discover work that Precision has supported.

Explore our blog
Read: Case Study: Biomarker-Driven Enrollment Using Notch Mutation Targeting Case Study: Biomarker-Driven Enrollment Using Notch Mutation Targeting

Oncology

Case Study: Biomarker-Driven Enrollment Using Notch Mutation Targeting

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=164725548848, hs_child_table_id=0, hs_updated_at=1754641451547, hs_published_at=1759436220388, description=Alexis Hobbins-White is an accomplished leader who plays a pivotal role in navigating the complex landscape of global oncology and rare disease-focused clinical trials. With a career spanning over 15 years in the clinical trials industry, Alexis brings a wealth of experience across multiple therapeutic areas, showcasing her proficiency in diverse aspects of operational strategy. She specializes in early phase adaptive studies, particularly in immuno-oncology and advanced therapeutics. She has an MSc in Neuroscience and an MA in Biotechnology Law and Ethics., avatar=Image{width=287,height=287,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/PfMxMarkentive/authors/Alexis-Hobbins.png',altText='Alexis-Hobbins',fileId=194096322982}, linkedin=https://www.linkedin.com/in/alexis-hobbins-white-400a1720/, lastname=Hobbins-White, hs_initial_published_at=1713362276020, hs_created_by_user_id=5166971, hs_created_at=1713361952861, hs_is_edited=false, hs_deleted_at=0, name=Alexis, job=Senior Director, Operational Strategy , slug=alexis-hobbins-white, hs_updated_by_user_id=78347666}, second={}, third={}})
  • Alexis Hobbins-White avatar

    Alexis Hobbins-White
Discover
Read: Case Study: Global Phase 1-2 TCR Therapy in Advanced Solid Tumors Case Study: Global Phase 1-2 TCR Therapy in Advanced Solid Tumors

Oncology

Case Study: Global Phase 1-2 TCR Therapy in Advanced Solid Tumors

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=164725548848, hs_child_table_id=0, hs_updated_at=1754641451547, hs_published_at=1759436220388, description=Alexis Hobbins-White is an accomplished leader who plays a pivotal role in navigating the complex landscape of global oncology and rare disease-focused clinical trials. With a career spanning over 15 years in the clinical trials industry, Alexis brings a wealth of experience across multiple therapeutic areas, showcasing her proficiency in diverse aspects of operational strategy. She specializes in early phase adaptive studies, particularly in immuno-oncology and advanced therapeutics. She has an MSc in Neuroscience and an MA in Biotechnology Law and Ethics., avatar=Image{width=287,height=287,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/PfMxMarkentive/authors/Alexis-Hobbins.png',altText='Alexis-Hobbins',fileId=194096322982}, linkedin=https://www.linkedin.com/in/alexis-hobbins-white-400a1720/, lastname=Hobbins-White, hs_initial_published_at=1713362276020, hs_created_by_user_id=5166971, hs_created_at=1713361952861, hs_is_edited=false, hs_deleted_at=0, name=Alexis, job=Senior Director, Operational Strategy , slug=alexis-hobbins-white, hs_updated_by_user_id=78347666}, second={}, third={}})
  • Alexis Hobbins-White avatar

    Alexis Hobbins-White
Discover
Read: FDA Draft Guidance on Overall Survival in Oncology Trials – What Sponsors Need to Know FDA Draft Guidance on Overall Survival in Oncology Trials – What Sponsors Need to Know

Clinical Trials - Regulatory - Oncology

FDA Draft Guidance on Overall Survival in Oncology Trials – What Sponsors Need to Know

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=195804116748, hs_child_table_id=0, hs_updated_at=1757700176991, hs_published_at=1759436220388, description=John is an experienced regulatory affairs consultant with more than 15 years of professional experience in drug development. He brings a proven track record in providing regulatory strategy, regulatory document development and review, and liaising with regulatory authorities., avatar=Image{width=1000,height=1000,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/John%20McIntyre.jpg',altText='John McIntyre',fileId=195809756215}, lastname=McIntyre, PhD, hs_initial_published_at=1757516163742, hs_created_by_user_id=26433386, hs_created_at=1757515873736, hs_is_edited=false, hs_deleted_at=0, name=John, job=Senior Director, Regulatory Strategy, slug=john-mcintyre, hs_updated_by_user_id=78347666}, second={hs_id=195804116749, hs_child_table_id=0, hs_updated_at=1757598950007, hs_published_at=1759436220388, description=An expert in hematology and oncology and a veteran of the FDA with almost nine years of experience, culminating as a Deputy Director for the Division of Hematologic Malignancies 2. Possesses a profound understanding of regulatory strategy, particularly in the development of CAR-T cell therapies, bispecifics and T-cell engagers. Spearheaded initiatives to develop novel endpoints in blood cancer such as minimal residual disease (MRD) in lymphoma and chronic lymphocytic leukemia (CLL.), avatar=Image{width=1000,height=1000,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/Nick%20Richardson.jpg',altText='Nick Richardson',fileId=195807970451}, linkedin=https://www.linkedin.com/in/nicholas-richardson-do-mph-049784113/, lastname=Richardson, DO, MPH, hs_initial_published_at=1757516163742, hs_created_by_user_id=26433386, hs_created_at=1757516077087, hs_is_edited=false, hs_deleted_at=0, name=Nick, job=Vice President, Clinical Development, slug=nick-richardson, hs_updated_by_user_id=78347666}, third={}})
  • John M. avatar

    John M.
  • Nick R. avatar

    Nick R.
Discover